This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

John Higgins Biography and Net Worth

CEO of Ligand Pharmaceuticals

John L. Higgins is Chief Executive Officer and a member of the Board of Directors of Ligand. Prior to joining our company, Mr. Higgins served as Chief Financial Officer at Connetics Corporation, a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations & governance committee of Bio-Techne Corporation, a publicly-traded life sciences services. Mr. Higgins has served as a director on numerous public and private companies. He also serves as the chairperson of the board of trustees of Academy of Whole Learning, a non-profit organization dedicated to providing educational and therapy services to children of underrepresented communities. He graduated Magna Cum Laude from Colgate University with an A.B. in economics.

What is John L. Higgins' net worth?: The estimated net worth of John L. Higgins is at least $274.74 million as of May 23rd, 2023. Mr. Higgins owns 2,462,686 shares of Ligand Pharmaceuticals stock worth more than $274,737,250 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Higgins may own. Learn More about John L. Higgins' net worth.
How do I contact John L. Higgins?: The corporate mailing address for Mr. Higgins and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected]. Learn More on John L. Higgins' contact information.
Has John L. Higgins been buying or selling shares of Ligand Pharmaceuticals?: John L. Higgins has not been actively trading shares of Ligand Pharmaceuticals during the last ninety days. Most recently, John L. Higgins sold 10,000 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $61.87, for a transaction totalling $618,700.00. Following the completion of the sale, the director now directly owns 422,984 shares of the company's stock, valued at $26,170,020.08. Learn More on John L. Higgins' trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Matthew Foehr (COO), and John Higgins (CEO). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $243,475.00. During the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 79,049 shares worth more than $7,559,608.80. The most recent insider tranaction occured on September, 23rd when COO Matthew E Korenberg sold 9,772 shares worth more than $989,121.84. Insiders at Ligand Pharmaceuticals own 5.9% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 9/23/2024.

John L. Higgins Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2022	Sell	10,000	$61.87	$618,700.00	422,984
11/17/2022	Sell	10,000	$78.32	$783,200.00	416,731
9/15/2022	Sell	2,000	$90.00	$180,000.00	367,180
11/12/2021	Sell	3,000	$160.50	$481,500.00
1/27/2021	Sell	40,000	$182.00	$7,280,000.00	285,310
1/25/2021	Sell	50,000	$159.00	$7,950,000.00	285,310
7/31/2019	Buy	1,850	$95.45	$176,582.50	146,749
5/14/2019	Buy	2,500	$113.50	$283,750.00	28,042
3/13/2019	Buy	2,500	$114.29	$285,725.00	141,399
8/30/2018	Sell	3,500	$258.25	$903,875.00	85,419
8/17/2018	Sell	34,500	$241.96	$8,347,620.00	110,426
5/15/2018	Sell	12,405	$179.97	$2,232,527.85	119,824
2/15/2018	Sell	9,000	$157.03	$1,413,270.00	102,700
1/24/2018	Sell	22,500	$165.00	$3,712,500.00	111,700
1/19/2018	Sell	28,099	$153.70	$4,318,816.30	162,299
11/16/2017	Sell	5,269	$142.53	$750,990.57	143,542
9/5/2017	Sell	5,000	$130.00	$650,000.00	144,171
8/8/2017	Sell	5,483	$125.00	$685,375.00	144,654
6/21/2017	Sell	4,666	$120.00	$559,920.00	143,837
6/9/2017	Sell	12,000	$114.87	$1,378,440.00	151,171
3/20/2017	Sell	4,000	$109.10	$436,400.00	139,171
9/22/2016	Sell	3,000	$117.34	$352,020.00	122,664
3/7/2016	Sell	10,833	$102.47	$1,110,057.51	120,220
6/9/2015	Sell	10,000	$92.88	$928,800.00
8/15/2014	Buy	1,000	$54.97	$54,970.00
10/18/2013	Sell	10,000	$55.00	$550,000.00
12/5/2012	Buy	2,000	$18.03	$36,060.00

John L. Higgins Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $111.56

$109.53

$112.00

50 Day Range

MA: $107.71

$97.37

$129.90

2 Week Range

Now: $111.56

$57.00

$129.90

Volume

133,450 shs

Average Volume

144,630 shs

Market Capitalization

$2.11 billion

P/E Ratio

44.45

Dividend Yield

N/A

Beta

0.99

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad